MedTrace Logo

Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy

NCT01434212 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2011-10-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether the outcome of interferon therapy on HCV infected patients can be early precisely predicted with a novel mathematic method with Chinese population.

Conditions

  • Hepatitis

Interventions

DRUG

Interferon Alfa-2b, Ribavirin

Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection. Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally.

Sponsors & Collaborators

  • Chinese Academy of Sciences

    collaborator OTHER_GOV

  • The First Hospital of Jilin University

    lead OTHER

Principal Investigators

  • Junqi Niu, PhD/MD · First Hospital Jilin University

  • Bing Sun, PhD/MD · Chinese Academy of Sciences

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01434212 on ClinicalTrials.gov